BiOptic Inc. was listed on Taiwan’s Emerging Stock Board from Q4, 2021

BiOptic Inc.’s self-developed COVID-19 test kit has been formally submitted to the European Union a few days ago to apply for in vitro diagnostic medical device (CE-IVD) certification. After review and approval, it can be marketed and sold in the European Union. The selection of oral examination and physical examination has allowed people to increase their willingness to test for the COVID-19 virus and implement regional COVID-19 epidemic prevention work.

Since the outbreak of the COVID-19 virus in 2019, it has undergone multiple mutations of the virus strain. At the end of 2021, the Omicron variant virus strain has become the mainstream virus of COVID-19 virus in many countries. In the face of the threat of the epidemic, global epidemic prevention regulations and isolation policies have been continuously updated. The demand for testing has increased accordingly.

BiOptic Inc. has developed a test based on the oral specimen of the subject, which is different from the current most common nasopharyngeal inspection method. Since there is no "discomfort" during the inspection, it is easier to be accepted by the public.

BiOptic Inc. has deployed the global molecular biotechnology research market for nearly two decades. With the establishment of a global distribution network, professionals from more than 50 countries have obtained a good user experience. The main product is "Qsep Series Biological Fragment Analyzer" which is also widely used in the fields of genetic testing and clinical diagnosis.

The R&D team has successfully developed various testing reagent kits, to support the instrument business and increase product shipments gradually. In addition to the application market expansion, it has also driven the sales of Qsep series platforms and cassette consumables, and boosted the company's revenue growth momentum.

BiOptic Inc., which was listed on Taiwan’s Emerging Stock Board in October ( https://www.tpex.org.tw/web/regular_emerging/apply_schedule/applicant_emerging/applicant_emerging_companies.php?l=en-us&stk_code=6850&select_year=2021 ), continued to record high revenue in the fourth quarter; consolidated revenue of NT$24.298 million in November was a record high. The cumulative combined revenue from January to November has exceeded 152 million New Taiwan dollars, an increase of 54.34% over the same period in 2020, which is the same as a record high, and the profit is better than previous years.

Looking forward to 2022, BiOptic Inc. will continue to pursue rapid growth in its operations.

Original news page:

https://www.chinatimes.com/newspapers/20211228000184-260210?chdtv